Zobrazeno 1 - 10
of 70
pro vyhledávání: '"L S Zubarovskaya"'
Publikováno v:
Терапевтический архив, Vol 87, Iss 7, Pp 88-93 (2015)
Aim. To study the incidence and risk factors of bacterial infections and the efficiency of empirical antibacterial therapy in patients in the early period after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Subjects and methods. The
Externí odkaz:
https://doaj.org/article/3561b3287d5b4faf9481ce220baea60b
Autor:
T. V. Antonova, O. E. Pobegalova, O. V. Gorchakova, L. S. Zubarovskaya, O. S. Yudinceva, D. A. Lioznov
Publikováno v:
Журнал инфектологии, Vol 15, Iss 4, Pp 62-69 (2024)
Study objective: to evaluate frequency of CMV, HHV-6, and EBV reactivation in children within 60 days after HSCT.Materials and methods: The study was carried out in Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology, and
Externí odkaz:
https://doaj.org/article/e73544a6014f4791b34f12fb3bb4f663
Autor:
L. P. Mendeleeva, V. G. Savchenko, L. S. Lubimova, I. A. Demidova, B. V. Afanassiev, L. S. Zubarovskaya, T. P. Zagoskina, I. S. Zuzgin, T. S. Konstantinova, V. A. Lapin, I. A. Lisukov, A. B. Loginov, N. A. Obidina, V. A. Rossiev, S. V. Shamansky
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 38-45 (2022)
Russian Interregional Register of hematopoietic stem cell transplantation was established in 2000. 11 transplant centres from 7 Russian cities are including in Register now. In this analysis we applied transplant activity survey data from 01.01.1996
Externí odkaz:
https://doaj.org/article/3884df5b6b8f4ec1aa9ee0195d96e778
Autor:
A. S. Frolova, A. G. Volkova, O. V. Paina, P. V. Kozhokar, K. A. Ekushov, Zh. Z. Rakhmanova, L. A. Cvetkova, E. D. Dobrovolskaya, B. I. Smirnov, E. A. Kulagin, T. A. Bykova, E. V. Semenova, L. S. Zubarovskaya
Publikováno v:
Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, Vol 29, Iss 3, Pp 81-90 (2022)
Relevance. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) makes it possible to treat severe malignant and non-malignant hematopoietic disorders system. Pulmonary complications (PC) occur in 40–60 % of patients after allo-HSCT. Howev
Externí odkaz:
https://doaj.org/article/4798da693be74e02beec0aebcaf1a834
Autor:
M. M. Kanunnikov, J. Z. Rakhmanova, M. V. Barabanshikova, N. V. Levkovsky, A. I. Wafina, O. V. Paina, T. A. Bykova, Е. V. Semenova, О. V. Goloshapov, E. V. Morozova, I. S. Mоiseev, L. S. Zubarovskaya
Publikováno v:
Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, Vol 27, Iss 4, Pp 62-70 (2021)
Introduction. Sinusoidal obstructive syndrome (SOS)/veno-occlusive liver disease (VOD) is one of the most dangerous complication of allogeneic hematopoietic stem cell transplantation (alloHSCT).The objective of our study was to analyze risk factors a
Externí odkaz:
https://doaj.org/article/862fc09720c946678588c33ff6d4150f
Autor:
Yu. A. Rogacheva, M. O. Popova, I. V. Markova, O. V. Paina, D. I. Shmidt, O. N. Pinegina, I. Yu. Nikolaev, L. S. Zubarovskaya, N. N. Klimko
Publikováno v:
Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, Vol 27, Iss 4, Pp 80-87 (2021)
Malassezia spp. is a commensal yeast that represents normal microflora in humans and some animals. However, Malassezia spp. can cause life-threatening invasive mycosis. Evidence on Malassezia spp. infections is limited mostly to a case reports descri
Externí odkaz:
https://doaj.org/article/e2dc5de997a34306afa38483c3c9c15e
Autor:
O. V. Goloshchapov, A. B. Chukhlovin, E. A. Bakin, O. V. Stanevich, R. V. Klementeva, A. A. Shcherbakov, A. N. Shvetsov, M. A. Suvorova, S. N. Bondarenko, M. A. Kucher, A. D. Kulagin, L. S. Zubarovskaya, I. S. Moiseev
Publikováno v:
Терапевтический архив, Vol 92, Iss 7, Pp 43-54 (2020)
Aim.Was to evaluate clinical efficacy, adverse events and changes in the gut microbiome after fecal microbiota transplantation (FMT) in patients with gastrointestinal (GI) form of graft-versus-host disease (GVHD). Materials and methods.The prospec
Externí odkaz:
https://doaj.org/article/008ab8b4b3d346f7b08fbcda36f33c2e
Autor:
T. V. Yukhta, I. V. Kazantsev, A. G. Gevorgyan, P. S. Tolkunova, A. V. Kozlov, D. A. Zvyagintseva, T. V. Andreeva, B. I. Smirnov, E. V. Morozova, S. A. Safonova, Yu. А. Punanov, L. S. Zubarovskaya, B. V. Afanasyev
Publikováno v:
Онкогематология, Vol 14, Iss 4, Pp 47-58 (2019)
Background. Ewing sarcoma (EWS) is a second most common pediatric bone tumor. About one quarter of all patients belong to a high-risk group characterized by a poor prognosis. In spite of high-dose chemotherapy (HDCT) with autologous hemopoietic stem
Externí odkaz:
https://doaj.org/article/5a353a2d0c8746a2b506228825e190a6
Autor:
O. V. GOLOSHCHAPOV, D. V. CHURAKINA, M. А. KUCHER, R. V. KLEMENTEVA, S. V. SIDORENKO, V. V. GOSTEV, V. Е. KAREV, М. А. SUVOROVA, I. V. SHLYK, А. B. CHUKHLOVIN, L. S. ZUBAROVSKAYA, B. V. AFANASYEV
Publikováno v:
Вестник анестезиологии и реаниматологии, Vol 16, Iss 3, Pp 63-73 (2019)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective method to treat malignancy and some solid tumors which may be accompanied by life-threatening immune and infectious complications refractory to standard immunosuppressive
Externí odkaz:
https://doaj.org/article/ef7e2e0d835b4d2784959be54c09cf47
Autor:
A. S. Borovkova, O. V. Paina, P. V. Kozhokar, Zh. Z. Rakhmanova, A. A. Osipova, L. A. Tsvetkova, T. A. Bykova, O. A. Slesarchuk, I. S. Moiseev, E. V. Semenova, A. D. Kulagin, L. S. Zubarovskaya
Publikováno v:
Pediatric Hematology/Oncology and Immunopathology. 22:32-43
Acute myeloid leukemia (AML) is the second most common type of leukemia in children and accounts for up to 20 % of all leukemias. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective, and sometimes the only therapeutic optio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::842e9293ea136d3e8d9ece2b630707b9
https://doi.org/10.24287/1726-1708-2023-22-2-32-43
https://doi.org/10.24287/1726-1708-2023-22-2-32-43